CD8A and neoplasm: Strikingly, analysis of the antitumor immune response directed against the OVA epitope SIINFEKL 11 days post-depletion revealed a ~100-fold increase in the frequency of tumor-specific CD8+ T cells in both the spleen and TdLN (Figure 6F).